Homologous recombination is essential for chromosome segregation during meiosis I. Meiotic recombination is initiated by the introduction of double-strand breaks (DSBs) at specific genomic locations called hotspots, which are catalyzed by Spo11 and its partners. DSB hotspots during meiosis are marked with Set1-mediated histone H3K4 methylation. The Spo11 partner complex, Rec114-Mer2-Mei4, essential for the DSB formation, localizes to the chromosome axes. For efficient DSB formation, a hotspot with histone H3K4 methylation on the chromatin loops is tethered to the chromosome axis through the H3K4 methylation reader protein, Spp1, on the axes, which interacts with Mer2. In this study, we found genetic interaction of mutants in a histone modification protein complex called PAF1C with the REC114 and MER2 in the DSB formation in budding yeast Saccharomyces cerevisiae. Namely, the paf1c mutations rtf1 and cdc73 showed synthetic defects in meiotic DSB formation only when combined with a wild-type-like tagged allele of either the REC114 or MER2. The synthetic defect of the tagged REC114 allele in the DSB formation was seen also with the set1, but not with spp1 deletion. These results suggest a novel role of histone modification machinery in DSB formation during meiosis, which is independent of Spp1-mediated loop-axis tethering.
The CXCL13 chemokine plays a crucial role in guiding B cell migration to the light zones (LZs) during the germinal center (GC) reaction. While CXCL13 expression is absent in most cell types, aberrant amplification of the CXCR5-CXCL13 signaling is observed in various cancers, including germinal center-derived B-lymphomas (GCDBL), colorectal adenocarcinoma (COAD), and liver hepatocellular carcinoma (LIHC). However, the molecular mechanisms underlying abnormal CXCL13 transcription in cancer cells and its functional consequences remain elusive. We identify DNA-CpG methylation binding protein 1 (MBD1) as a suppressor of CXCL13 expression. Chromosomal conformation capture (3C) analysis reveals a distal super-enhancer located near CCNG2 that interacts with the CXCL13 promoter in GCDBL, suggesting that enhancer-hijacking drives the aberrant expression. Our functional validation demonstrates that CXCR5-CXCL13 signaling suppresses p53 and its target genes in GCDBLs, COAD, and LIHC. Notably, CXCL13 in the GCDBL cell line Raji disrupts CXCR5-mediated migration, a mechanism essential for (light zone) LZ-entry and affinity maturation of GC B cells. These findings highlight the dual role of the CXCR5-CXCL13 axis in immune response and cancer proliferation. Key Points: Super-enhancer near CCNG2 region interacts with CXCL13-TSS driving CXCL13 in cancers. Aberrant CXCL13 prevents CXCR5-mediated migration of B-lymphomas and promotes growth and p53 dysregulation in CXCR5+ cells CXCR5-CXCL13 axis impairs p53 target gene expression and promotes tumor growth Abstract Figure: Highlights: Aberrant CXCL13 expression in hematological and solid cancers Chemotherapeutic treatment of cancer cells promotes CXCL13 and CXCR5 expression Distal super-enhancer on CCNG2 interacts with CXCL13 promoter CXCL13 expression in B-lymphomas prevents CXCR5-dependent migration CXCR5-CXCL13 axis encounters p53 function in hematological and solid cancer cells
B cell receptor signaling, NF-κB signaling, BCL6 and p53 regulation are essential for germinal center (GC) B cell fate. Dysregulation of these pathways drives the pathogenesis and treatment resistance of GC-derived B-lymphomas (GCDBL). To explore how these pathways affect GCDBL fate and pathogenesis, we treated Raji cells (a GCDBL and Burkitt’s lymphoma) with mild hydroxyurea (HU) to simulate genotoxic stress encountered by GC B cells. Genome-wide mapping of histone H3K4me3 and p53 target analysis in HU-treated Raji cells combined with transcriptome analysis of human tonsil GC B cells identified ATAD2B (a p53 target) as differentially expressed. We found that p53 suppresses ATAD2B and ATAD2 , while ATAD2 and BCL6 transcripts positively correlate in DLBCLs, suggesting that p53 regulates BCL6 in GC B cells via ATAD2 suppression. We propose that p53 regulation of BCL6 quality assures GC B cells before GC exit. Unlike BCL6 suppression of IFN-γ and NF-κB signaling in GC B cells, we identified IFNGR1 as a loosely bound BCL6 target and observed loss of BCL6 regulation on genes encoding inhibitory subunits of NF-κB signaling in B-lymphoma treated with a Bruton tyrosine kinase (BTK) inhibitor. These adaptations, alongside with prevalent genetic inactivation of NF-κB inhibitory genes in DLBLCs, likely contribute to DLBCL pathogenesis and therapy resistance. Our findings highlight the pivotal role of the p53-BCL6 axis in GC B cell fate and its dysregulation in DLBCL pathogenesis and chemoresistance. Key Highlights: Genes induced in human Burkitt’s lymphoma under genotoxic stress are largely independent of histone H3K4me3 marks at transcriptional start sites (TSS). Loss of BCL6 regulation on genes encoding components of IFN-γ signaling is associated with reduced survival and the pathogenesis of DLBCL. Inactivating mutations in genes encoding components of the NF-κB inhibitory subunit serve as an adaptation for DLBCL pathogenesis. BCL6 expression is correlated with ATAD2 overexpression in DLBCL and solid tumors.
The CXCL13 chemokine expression is developmentally restricted to few cell types including T, B and dendritic cells. Aberrant amplification of CXCL13 expres
BCL6 is a master transcriptional regulator of germinal center (GC) B cells. BCL6 is frequently translocated at the major translocation cluster (MTC) within intron 1 of the BCL6 locus, a hotspot commonly rearranged in diffuse large B cell lymphomas (DLBCLs). BCL6 amplifications are associated with therapeutic resistance and poor survival outcomes in hematological and solid cancers. However the mechanisms suppressing genome instability at the BCL6 -MTC preventing BCL6 rearragements remain unclear. Here, transcriptome analysis and genome-wide mapping of histone H3 lysine 4 trimethylation (H3K4me3) in hydroxyurea (HU)-treated Raji cells (a Burkitt’s lymphoma model) revealed the induced expression of MBD1 , encoding the DNA CpG methylation-binding protein. Functional studies using shRNA silencing and ectopic overexpression demonstrated that MBD1 suppresses BCL6 transcription whose promoter harbours conserved CpG methylation sites, suggesting a DNA methylation-dependent regulation of BCL6 trasncription by MBD1. Conversely, BCL6 repressed MBD1 expression by binding to its promoter. MBD1 -depleted Raji cells exhibited increased genomic instability at the BCL6 -MTC upon HU treatment, heightened sensitivity to DNA replication inhibitors (HU, gemcitabine, and etoposide), and reduced tumorigenicity in xenograft mouse models. We propose that MBD1 prevents genomic instability at the BCL6 -MTC to suppress DLBCL formation. Moreover, MBD1 promotes genomic stability and cell viability during DNA replication stress. MBD1 thus represents a potential therapeutic target for cancers exhibiting resistance to chemotherapies targeting DNA replication. Key Points: MBD1 suppresses BCL6 expression under the DNA replication stress MBD1 suppresses genomic instability at BCL6 translocation hotspots MBD1 depletion is associated with reduced tumorigenicity in mouse xenograft and sensitivity to DNA replication inhibitors.
Activation-Induced Cytidine Deaminase (AID) induces DNA double-strand breaks (DSBs) at the switch (S) regions of the Immunoglobulin heavy chain ( Igh ) locus, which are essential for Class Switch Recombination (CSR) and Somatic Hypermutation (SHM), key processes for effective antibody production. While AID activity is critical, its off-target effects, such as DSBs at the Myc locus, can cause chromosomal translocations like Igh–Myc fusions, contributing to B-cell lymphomas. The factors assembled on Igh locus that tether AID-induced DSBs and subsequently the CSR, remain unknown. To address this, we developed a method to isolate CSR-specific factors by inserting a 5X-GAL4-UAS sequence at the switch-mu ( Sµ ) region in CH12 cells. This engineered site enables recruitment of a 3-FLAG-GAL4 DNA-binding protein (3F-GAL4-DBD), allowing specific pulldown of proteins enriched at the Sµ region. Successful recovery of BRD2 from the Sµ region, a known CSR regulator, validated this approach. Characterizing these factors may uncover novel regulators of CSR and highlight mechanisms that balance antibody diversification with genomic integrity in B cells.